1-20 of 28,785 results for subject:Screening
Librarians' tools
- Search time
- 0.448 seconds
- Solr query time
- 0.032 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, whether it remains Government policy that a man who requests a PSA test following an informed discussion with their GP should be able to receive that test.
To ask the Secretary of State for Health and Social Care, whether it remains Government policy that a man who requests a PSA test following an informed discussion with their GP should be able to receive that test.
I refer the Hon. Member to the answer provided on 16 November in response to Question 41483.
To ask the Secretary of State for Health and Social Care, whether the UK National Screening Committee’s base-case cost-effectiveness analysis for the March 2026 prostate cancer screening recommendation applied a discount rate of 3.5% per annum to both costs and health effects.
To ask the Secretary of State for Health and Social Care, whether the UK National Screening Committee’s base-case cost-effectiveness analysis for the March 2026 prostate cancer screening recommendation applied a discount rate of 3.5% per annum to both costs and health effects.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 November 2026 to Question 40120, whether the HMT Green Book discount rate of 1.5% per annum on health effects was tested by the UK National Screening Committee only as part of a sensitivity...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 November 2026 to Question 40120, whether the HMT Green Book discount rate of 1.5% per annum on health effects was tested by the UK National Screening Committee only as part of a sensitivity...
To ask the Secretary of State for Health and Social Care, pursuant to the response of 9 November 2026 to Question 40120, what the base-case Incremental Cost-Effectiveness Ratio would have been had the Green Book rate of 1.5% on health effects been applied with the £20,000 per QALY threshold held...
To ask the Secretary of State for Health and Social Care, pursuant to the response of 9 November 2026 to Question 40120, what the base-case Incremental Cost-Effectiveness Ratio would have been had the Green Book rate of 1.5% on health effects been applied with the £20,000 per QALY threshold held...
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that the rollout of rapid genomic testing for brain tumours is supported by consistent national standards for tumour tissue handling and preservation, including the retention of suitable surplus tissue for future...
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that the rollout of rapid genomic testing for brain tumours is supported by consistent national standards for tumour tissue handling and preservation, including the retention of suitable surplus tissue for future...
Professor Anthony Chalmers, Chair of the Brain Tumour Group within the UK Collaborative for Cancer Clinical Research, will set out further detail on the expert review, including its scope, in due course. NHS England has completed a gap analysis of the need for additional brain tumour tissue freezing capacity and is considering how best to support an equitable expansion of capacity. The Department and NHS England are also working with professional bodies to review tissue retention guidance and consent processes.
NHS England has produced national sample-handling guidance for solid tumours, including for whole genome sequencing, to standardise the collection, processing, and transport of tumour samples. This guidance helps maintain DNA quality and supports consistent access to precision diagnostics, includes consideration of the handling of fresh tissue samples, and sets out approaches designed to support genomic testing.
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Minister for Public Health and Patient Safety during the debate on Prostate Cancer Screening of 26 October 2026, Official Report, column 24WH, what steps her Department plan to take with the...
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Minister for Public Health and Patient Safety during the debate on Prostate Cancer Screening of 26 October 2026, Official Report, column 24WH, what steps her Department plan to take with the...
I refer the Hon Member to the answer provided on 9 July in response to Question 11285.
To ask the Secretary of State for Health and Social Care, what estimate her Department has made of the proportion of men in the UK that carry a pathogenic BRCA2 variant that have not had this yet confirmed via genetic testing.
To ask the Secretary of State for Health and Social Care, what estimate her Department has made of the proportion of men in the UK that carry a pathogenic BRCA2 variant that have not had this yet confirmed via genetic testing.
I refer the Hon Member to the answer provided on 9 July in response to Question 11285.
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 10 September 2026 to Question 19922, and with reference to the Minister for Public Health and Patient Safety’s comments on prostate specific antigen (PSA) testing during the Westminster Hall Debate on 26 October 2026,...
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 10 September 2026 to Question 19922, and with reference to the Minister for Public Health and Patient Safety’s comments on prostate specific antigen (PSA) testing during the Westminster Hall Debate on 26 October 2026,...
I refer the Hon. Member to the answer provided on 10 September in response to Question 19922.
To ask the Secretary of State for Health and Social Care, if she will ask the UK National Screening Committee to review the evidence on lowering the starting age for bowel cancer screening in England from 50 to 40.
To ask the Secretary of State for Health and Social Care, if she will ask the UK National Screening Committee to review the evidence on lowering the starting age for bowel cancer screening in England from 50 to 40.
To ask the Secretary of State for Health and Social Care, when the upper age limit of 71 for automatic invitations to NHS breast screening was last reviewed; what assessment his Department has made of the potential merits and risks of extending routine invitations to women aged 72 to 79;...
To ask the Secretary of State for Health and Social Care, when the upper age limit of 71 for automatic invitations to NHS breast screening was last reviewed; what assessment his Department has made of the potential merits and risks of extending routine invitations to women aged 72 to 79;...
To ask the Secretary of State for Health and Social Care, when the UK National Screening Committee plans to (a) begin and (b) complete its review of screening for adolescent idiopathic scoliosis; and what the reasons are for the delay.
To ask the Secretary of State for Health and Social Care, when the UK National Screening Committee plans to (a) begin and (b) complete its review of screening for adolescent idiopathic scoliosis; and what the reasons are for the delay.
To ask the Secretary of State for Health and Social Care, under what circumstances GPs are recommended to order fungal tests for patients.
To ask the Secretary of State for Health and Social Care, under what circumstances GPs are recommended to order fungal tests for patients.
It is for general practitioners to use their clinical judgement when assessing patients, including when ordering diagnostic tests, taking account of their symptoms and individual circumstances.
The Department of Health and Social Care has published guidance with the UK Health Security Agency and the Ministry of Housing, Communities and Local Government on understanding and addressing the health risks of damp and mould in the home, which is available at the following link:
I absolutely join the hon. Lady in giving attention to World Diabetes Day and the important work done by Diabetes UK. I have had a personal family interest in these matters for some years, and I know the importance of early diagnosis and the effect that diabetes can have if...
I absolutely join the hon. Lady in giving attention to World Diabetes Day and the important work done by Diabetes UK. I have had a personal family interest in these matters for some years, and I know the importance of early diagnosis and the effect that diabetes can have if...
Saturday 14 November is World Diabetes Day, and it is estimated that around 6 million people in the UK live with diabetes. The theme this year is early diagnosis and risk reduction, and I encourage Ministers to consider my ten-minute rule Bill, the Type 1 Diabetes Screening (Children) Bill, about...
Saturday 14 November is World Diabetes Day, and it is estimated that around 6 million people in the UK live with diabetes. The theme this year is early diagnosis and risk reduction, and I encourage Ministers to consider my ten-minute rule Bill, the Type 1 Diabetes Screening (Children) Bill, about...
Earlier this week, I attended a drop-in session organised by Cardiac Risk in the Young to show my support for the introduction of a screening programme that could save the lives of the 12 young people who die each week with undiagnosed heart issues. Whenever we go to these sessions,...
Earlier this week, I attended a drop-in session organised by Cardiac Risk in the Young to show my support for the introduction of a screening programme that could save the lives of the 12 young people who die each week with undiagnosed heart issues. Whenever we go to these sessions,...
I thank the hon. Gentleman for raising awareness of this serious issue. The Government are committed to shifting resources in the NHS from sickness to prevention, as is set out in our 10-year health plan and the new cardiovascular disease modern service framework. I am happy to raise those specific...
I thank the hon. Gentleman for raising awareness of this serious issue. The Government are committed to shifting resources in the NHS from sickness to prevention, as is set out in our 10-year health plan and the new cardiovascular disease modern service framework. I am happy to raise those specific...
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the funding and resource requirements for establishing an independent in-service evaluation of newborn screening for metachromatic leukodystrophy.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the funding and resource requirements for establishing an independent in-service evaluation of newborn screening for metachromatic leukodystrophy.
I refer the Hon. Member to the answer provided on 29 April in response to Question 124565.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of testing all pregnant people for Group B Streptococcus.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of testing all pregnant people for Group B Streptococcus.
I refer the Hon Member to the answer provided on 1 July in response to Question 10804.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits for introducing a mandatory clinical review for patients who have received five years of continuous oral bisphosphonate therapy for osteoporosis, including as part of the rollout of Fracture Liaison...
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits for introducing a mandatory clinical review for patients who have received five years of continuous oral bisphosphonate therapy for osteoporosis, including as part of the rollout of Fracture Liaison...
The National Institute for Health and Care Excellence (NICE) has published guidance on bisphosphonates for treating osteoporosis, which is available at the following link:
https://www.nice.org.uk/guidance/ta464
The guidance notes that there is uncertainty amongst clinical experts about the recommended treatment duration for someone prescribed a bisphosphonate. The guidance does not make any recommendations around how frequently patients prescribed oral bisphosphonate should receive a clinical review.
NICE is an independent body and is responsible for making decisions on whether its published guidelines should be updated in light of new evidence or emerging issues not in the scope of the original guideline. NICE maintains surveillance of new evidence that may affect its published guidance, and decisions on whether its guidance should be updated are taken through an established prioritisation process.
We continue to work closely with NHS England to improve access to fracture prevention services and to explore the best ways of supporting local systems to deliver high-quality care which meets the needs of their populations.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to raise awareness and improve self-referral uptake among older women for breast cancer.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to raise awareness and improve self-referral uptake among older women for breast cancer.
I refer the Hon Member to the answers provided on 20 April in response to Question 126985, on 30 October in response to Question 36506, and on 16 July in response to Question 14603. On the issue of self-referral, women aged 71 years old and over remain entitled to request a breast screening appointment every three years, and we work continually to ensure that awareness of that entitlement is reinforced through National Health Service communications.